| Business Summary | | Novogen
Limited
is
an
international
pharmaceutical
company.
The
Company's
work
began
with
naturally
occurring
isoflavones
found
in
the
human
diet,
which
has
since
led
to
the
discovery
and
development
of
phenolic
therapeutic
technology.
Isoflavones
are
a
group
of
phytoestrogens
found
only
in
legumes
like
chickpeas,
red
clover
and
lentils.
Currently,
Novogen
has
three
products
available.
All
products
are
dietary
supplements
containing
four
natural
isoflavones,
formononetin,
daidzein,
biochanin
A
and
genistein
(the
four
isoflavones),
which
are
considered
the
most
significant
in
terms
of
estrogenic
properties.
Promensil
is
indicated
for
the
management
of
menopausal
symptoms.
Rimostil
promotes
bone
and
heart
health
in
women.
Trinovin
has
been
developed
specifically
for
the
maintenance
of
the
health
of
men,
especially
those
over
the
age
of
50. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Novogen
Limited
is
engaged
in
pharmaceutical
research
and
development
and
manufacturing
and
marketing
of
health
supplements.
For
the
fiscal
year
ended
6/30/1999,
revenues
totalled
A$20.9
million,
up
from
A$6.4
million.
Net
loss
according
to
US
GAAP
totalled
A$17.9
million
vs.
income
of
A$493
thousand.
Revenues
reflect
an
increased
market
penetration
in
the
US
and
strong
growth
in
Australia.
Net
loss
reflects
costs
associated
with
promotion
efforts
in
the
US. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Graham Kelly, Ph.D. | Chairman | David Seaton | CFO | Chris Naughton | Managing
Director | Warren Lancaster | Vice-Pres | Ronald Erratt | Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|